What question did this study set out to answer?

The research aims to characterize the expression, role, and clinical significance of APOC1 across various cancer types.

June 27, 2026Discover OncologyOpen Access

Pan-cancer analysis identifies APOC1 as a TAM-derived modulator of adaptive immune resistance and predictor of therapeutic response

View Full Paper

Ask AI

Bookmark

Authors

Comprehensive analysis reveals APOC1 as a predictive biomarker of immune resistance in multiple cancer types, suggesting therapeutic targets.

The research aims to characterize the expression, role, and clinical significance of APOC1 across various cancer types.
Conducted multi-omic analysis of APOC1 across 33 cancer types using TCGA, GTEx, CPTAC data.
Assessed immune infiltration with seven algorithms, employing spatial transcriptomics and single-cell RNA sequencing to determine cellular sources.
Analyzed pharmacogenomic profiles associated with high APOC1 expression.
APOC1 upregulation associated with poor prognosis in KIRC, LGG, and STAD, independent of covariates and immune infiltration.
Identified tumor-associated macrophages (TAMs) as primary source of APOC1, correlating with immune checkpoint molecules.
High APOC1 tumors showed resistance to MAPK inhibitors but potential sensitivity to HDAC inhibitor Entinostat.

Yang et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

Comprehensive analysis reveals APOC1 as a predictive biomarker of immune resistance in multiple cancer types, suggesting therapeutic targets.